CA
RARE icon

Crewe Advisors’s Ultragenyx Pharmaceutical RARE Stock Holding History

Crewe Advisors’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-3
Closed -$107 – 636
2023
Q3 		$107 Hold
3
– – ﹤0.01% 562
2023
Q2 		$139 Buy
+3
New +$139 ﹤0.01% 787

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Crewe Advisors's RARE Position: Q4 2023 in Review

Crewe Advisors sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2023, closing a stake of 3 shares — an estimated $107 sold.

Crewe Advisors first reported a position in RARE in Q2 2023 and held it in 2 quarters. The position peaked at $139 in Q2 2023. 236 funds tracked by Wall St. Rank hold RARE as of Q4 2023.

  • Crewe Advisors reported no remaining Ultragenyx Pharmaceutical position as of Q4 2023 after selling out during the quarter.
  • Crewe Advisors sold 3 Ultragenyx Pharmaceutical shares in Q4 2023, an estimated $107.
  • Crewe Advisors first reported a position in Ultragenyx Pharmaceutical in Q2 2023 and held it in 2 quarters.
  • Crewe Advisors's Ultragenyx Pharmaceutical position peaked at $139 in Q2 2023.
  • 236 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2023.

Based on Crewe Advisors's 13F filing for Q4 2023, filed 9 Feb 2024.